Clinical Trial Update: Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of intralesional cemiplimab in adults with cutaneous squamous cell carcinoma or basal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Libtayo (cemiplimab) (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Phase 1 | Status: COMPLETED